JP2015505314A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505314A5 JP2015505314A5 JP2014551232A JP2014551232A JP2015505314A5 JP 2015505314 A5 JP2015505314 A5 JP 2015505314A5 JP 2014551232 A JP2014551232 A JP 2014551232A JP 2014551232 A JP2014551232 A JP 2014551232A JP 2015505314 A5 JP2015505314 A5 JP 2015505314A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pioglitazone
- alzheimer
- disease
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 82
- 238000000034 method Methods 0.000 claims 76
- 229960005095 pioglitazone Drugs 0.000 claims 41
- 208000024827 Alzheimer disease Diseases 0.000 claims 21
- 208000010877 cognitive disease Diseases 0.000 claims 20
- 230000002068 genetic effect Effects 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 208000028698 Cognitive impairment Diseases 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 15
- 108700028369 Alleles Proteins 0.000 claims 13
- 238000011282 treatment Methods 0.000 claims 13
- 239000002552 dosage form Substances 0.000 claims 11
- 239000007787 solid Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 101150101855 tomm-40 gene Proteins 0.000 claims 6
- 210000004556 brain Anatomy 0.000 claims 5
- 230000000971 hippocampal effect Effects 0.000 claims 5
- 239000007788 liquid Substances 0.000 claims 5
- 230000001537 neural effect Effects 0.000 claims 5
- 239000012472 biological sample Substances 0.000 claims 4
- 101000764216 Homo sapiens Mitochondrial import receptor subunit TOM40 homolog Proteins 0.000 claims 3
- 102100026905 Mitochondrial import receptor subunit TOM40 homolog Human genes 0.000 claims 3
- 239000003826 tablet Substances 0.000 claims 3
- 101150037123 APOE gene Proteins 0.000 claims 2
- 102100029470 Apolipoprotein E Human genes 0.000 claims 2
- 239000007894 caplet Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 230000003930 cognitive ability Effects 0.000 claims 2
- 230000006999 cognitive decline Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000007074 memory dysfunction Effects 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 1
- 239000002304 perfume Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/346,081 | 2012-01-09 | ||
| USPCT/US2012/020606 | 2012-01-09 | ||
| US13/346,081 US9102666B2 (en) | 2011-01-10 | 2012-01-09 | Methods and drug products for treating Alzheimer's disease |
| PCT/US2012/020606 WO2012096873A1 (en) | 2011-01-10 | 2012-01-09 | Methods and drug products for treating alzheimer's disease |
| US201261659872P | 2012-06-14 | 2012-06-14 | |
| US61/659,872 | 2012-06-14 | ||
| PCT/US2012/046692 WO2013106084A1 (en) | 2012-01-09 | 2012-07-13 | Methods and drug products for treating alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017111243A Division JP2017197554A (ja) | 2012-01-09 | 2017-06-06 | アルツハイマー病を治療する方法及び医薬品 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505314A JP2015505314A (ja) | 2015-02-19 |
| JP2015505314A5 true JP2015505314A5 (enExample) | 2015-09-03 |
Family
ID=48781795
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551232A Pending JP2015505314A (ja) | 2012-01-09 | 2012-07-13 | アルツハイマー病を治療する方法及び医薬品 |
| JP2017111243A Pending JP2017197554A (ja) | 2012-01-09 | 2017-06-06 | アルツハイマー病を治療する方法及び医薬品 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017111243A Pending JP2017197554A (ja) | 2012-01-09 | 2017-06-06 | アルツハイマー病を治療する方法及び医薬品 |
Country Status (2)
| Country | Link |
|---|---|
| JP (2) | JP2015505314A (enExample) |
| WO (1) | WO2013106084A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160345855A1 (en) * | 2013-12-13 | 2016-12-01 | Northwestern University | Methods of treating brain disorders or identifying biomarkers related thereto |
| JP2017001989A (ja) * | 2015-06-11 | 2017-01-05 | ニプロ株式会社 | 医薬組成物の製造方法及び医薬組成物 |
| GB201810492D0 (en) * | 2018-06-27 | 2018-08-08 | Cordeiro Maria Francesca | Composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| NZ710443A (en) * | 2008-08-12 | 2019-03-29 | Zinfandel Pharmaceuticals Inc | Method of identifying disease risk factors |
| US8846315B2 (en) * | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| AU2012205798B2 (en) * | 2011-01-10 | 2016-02-25 | Takeda Pharmaceutical Company Limited | Methods and drug products for treating Alzheimer's disease |
-
2012
- 2012-07-13 JP JP2014551232A patent/JP2015505314A/ja active Pending
- 2012-07-13 WO PCT/US2012/046692 patent/WO2013106084A1/en not_active Ceased
-
2017
- 2017-06-06 JP JP2017111243A patent/JP2017197554A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111065394B (zh) | 中枢神经系统病症的治疗 | |
| Cummings et al. | Pimavanserin: potential treatment for dementia-related psychosis | |
| JP7312169B2 (ja) | 遺伝性てんかん性障害の処置に使用するガナキソロン | |
| Yang et al. | Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder | |
| Ifteni et al. | Effectiveness and safety of rapid clozapine titration in schizophrenia | |
| RU2770050C2 (ru) | Способ лечения с применением традипитанта | |
| Pisciotta et al. | Alternating hemiplegia of childhood: pharmacological treatment of 30 Italian patients | |
| EP3512506B1 (en) | Use of pridopidine for treating rett syndrome | |
| AU2018383098B2 (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
| US20220162610A1 (en) | Novel rna transcript | |
| JP2022092013A (ja) | アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物 | |
| Łuc et al. | Tackling Alzheimer's disease: Hypothetical synergism between anti-inflammatory and anti-diabetic agents | |
| JP2015505314A5 (enExample) | ||
| JP2016528171A5 (enExample) | ||
| CN104906501A (zh) | 治疗银屑病的中药组分组合物 | |
| Swerdlow et al. | A pilot Study of oxaloacetate 100 mg capsules in Parkinson’s disease patients | |
| Baba et al. | Seven cases of late-life depression treated with cilostazol-augmented therapy | |
| Praharaj et al. | Sertraline-induced facial paresthesia | |
| Lin et al. | FRI0159 REAL-WORLD EVIDENCE OF EFFECTIVENESS OF SWITCHING FROM TOFACITINIB 5MG BID TO TOFACITINIB 11MG QD IN A COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS: A SINGLE-CENTER, OBSERVATIONAL STUDY IN TAIWAN | |
| CN118019540A (zh) | 用于治疗多发性硬化的lou064 | |
| Rabinowitz et al. | P. 3. a. 012 Age of onset of schizophrenia and outcomes in 29 placebo-controlled RCT's of antipsychotics in the NEWMEDS repository | |
| Terabe et al. | THU0129 The Effectiveness of Biologic Agents Concomitant with Tacrolimus in Rheumatoid Arthritis | |
| Bell et al. | P1‐445: Early evaluation of the safety, tolerability and pharmacokinetics of a novel 5HT6 receptor full antagonist for the treatment of the symptoms of mild‐to‐moderate dementia of the Alzheimer type | |
| Frogley et al. | Poster# 216 A RETROSPECTIVE STUDY OF CLOZAPINE IN EMOTIONALLY UNSTABLE PERSONALITY DISORDER | |
| CN108938645A (zh) | 一种抗精神病药物组合物 |